Simcere Pharmaceutical Group Limited recently finalized an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited concerning Rademikibart, an innovative IL-4Rα monoclonal antibody. This agreement grants Simcere exclusive rights for the development, manufacturing, and commercialization of Rademikibart in Greater China, while Connect retains its rights outside the region.

Rademikibart, also known as CBP-201, is a fully humanized monoclonal antibody designed to target IL-4Rα, a subunit of IL-4 and IL-13 receptors. By binding with IL-4Rα, Rademikibart effectively blocks the functions of IL-4 and IL-13, disrupting the Th2 inflammatory pathway and treating inflammatory diseases like atopic dermatitis (AD) and asthma.

Simcere will independently conduct future clinical trials for Rademikibart in Greater China, strategically strengthening its product portfolio in the autoimmune field. The collaboration aims to position Simcere more effectively in commercialization efforts.

Given the substantial patient populations associated with atopic dermatitis and asthma globally, Rademikibart holds promise as a candidate. Dupixent, the only approved IL-4Ra-targeting drug, has experienced considerable market growth, with global sales reaching 4.878 billion euros in the first half of 2023.

Jinsheng Ren, Simcere's Chairman and CEO, expressed enthusiasm about the agreement, emphasizing Rademikibart's potential and the opportunity to expand the immune diseases portfolio. The collaboration aims to bring more effective therapies to patients suffering from Th2 inflammatory diseases.

Simcere, an innovation-driven pharmaceutical company, focuses on therapeutic areas such as oncology, CNS, autoimmune, and anti-infection. Connect Biopharma is a global biopharmaceutical company specializing in T cell biology, aiming to develop therapies for chronic inflammatory diseases through innovative small molecules and antibodies.

 

Source: prnewswire.com

Report Abuse